Artificial Lung Market Size, Share & Industry Analysis, By Product Type (ECMO Artificial Lung Systems, ECCO₂R Systems, Artificial Lung Oxygenators, Portable Artificial Lung Systems, and Others), By Application (Acute Hypoxemic Respiratory Failure, Cardiopulmonary Failure, Chronic & End-Stage Lung Failure, and Others), By Patient Type (Adult and Pediatric), By End User (Hospitals, Academic & Research Institutes, and Others), and Regional Forecast, 2026–2034

The global artificial lung market size was valued at USD 1.28 billion in 2025. The market is projected to grow from USD 1.36 billion in 2026 to USD 2.34 billion by 2034, exhibiting a CAGR of 7.0% during the forecast period.

Artificial lungs are extracorporeal respiratory support technologies designed to perform or supplement pulmonary gas exchange by oxygenating blood and/or removing carbon dioxide when the patient's lungs cannot adequately perform these functions. The market includes ECMO artificial lung systems, extracorporeal carbon dioxide removal (ECCO₂R) systems, artificial lung oxygenators, portable artificial lung systems, and other related technologies. Market growth is majorly driven by the rising clinical need for extracorporeal respiratory support in severe acute respiratory failure, increasing utilization of ECMO for complex cardiopulmonary conditions, technological advancements in membrane oxygenators, and development of more compact and portable extracorporeal support systems. Further, improvements in hollow-fiber membranes, hemocompatibility, pump technology, monitoring, and circuit design are further supporting market expansion.

• For instance, in January 2026, the U.S. FDA granted 510(k) clearance to Medtronic's Bio-Medicus Life Support Catheter and Introducer, classified as a single-lumen ECMO cannula, supporting continued regulatory and technological activity across the extracorporeal life-support ecosystem.

Furthermore, Getinge AB, Medtronic plc, Fresenius Medical Care AG, Terumo Corporation, and LivaNova PLC are among the prominent companies operating in the global market.

ARTIFICIAL LUNG MARKET TRENDS

Growing Development of Compact and Portable Extracorporeal Respiratory Support Systems to Transform Critical Care

The market is witnessing increasing development of compact extracorporeal respiratory support technologies designed to improve mobility, simplify clinical workflows, and expand the potential use of extracorporeal support beyond conventional stationary intensive-care configurations. Traditional ECMO systems require pumps, oxygenators, tubing, monitoring systems, cannulation equipment, and highly trained clinical teams. Moreover, manufacturers are consequently focusing on reducing circuit complexity, improving membrane performance, lowering priming volumes, enhancing hemocompatibility, and integrating monitoring and control functions into more compact platforms. The trend is also supporting research into portable artificial lung systems that could provide longer-duration respiratory support and potentially bridge patients with chronic or end-stage lung disease to transplantation or recovery.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Clinical Utilization of Extracorporeal Respiratory Support for Severe Respiratory and Cardiopulmonary Failure to Drive Market Growth

Growing utilization of extracorporeal respiratory support in patients with severe respiratory and cardiopulmonary failure is prominently driving the global market. ECMO and related artificial lung technologies provide temporary gas-exchange support when conventional ventilation or other treatment approaches cannot adequately maintain oxygenation or carbon dioxide removal. These systems are particularly important for critically ill patients with acute hypoxemic respiratory failure, severe pulmonary insufficiency, cardiopulmonary failure, and selected cases requiring prolonged respiratory support. Expansion of specialized intensive-care infrastructure, increasing availability of ECMO-trained clinical teams, and improvements in pumps, oxygenators, cannulae, and monitoring technologies are supporting wider adoption.

MARKET RESTRAINTS

High Treatment Complexity and Risk of Serious Complications May Limit Market Growth

The complexity of extracorporeal respiratory support and potential for serious treatment-related complications are prominently restraining the global artificial lung market growth. ECMO and other extracorporeal systems require vascular cannulation, continuous blood circulation outside the body, anticoagulation, intensive monitoring, and specialized multidisciplinary expertise. Potential complications include bleeding, thrombosis, infection, hemolysis, vascular injury, air embolism, oxygenator failure, circuit malfunction, and neurological complications. Treatment is consequently concentrated primarily within hospitals possessing specialized intensive-care and perfusion capabilities. Device performance must also remain reliable during prolonged support, as circuit or oxygenator malfunction can require urgent component replacement.

MARKET OPPORTUNITIES

Expanding Applications of Artificial Lung Systems in Lung Transplantation to Create Growth Opportunities

The increasing utilization of artificial lung systems as a bridge to lung transplantation is creating significant growth opportunities in the market. Patients with end-stage respiratory diseases often require prolonged respiratory support while awaiting suitable donor organs. Artificial lung systems, including ECMO, can help maintain oxygenation and carbon dioxide removal during this period. Moreover, expanding lung transplantation programs, improving patient selection protocols, and increasing adoption of advanced respiratory support strategies are expected to create opportunities for manufacturers developing artificial lung technologies.

MARKET CHALLENGES

Maintaining Long-Term Hemocompatibility and Reliable Gas Exchange Challenges Market Expansion

Maintaining efficient gas exchange while minimizing adverse blood-material interactions remains a major technological challenge for artificial lung manufacturers. Blood circulating through extracorporeal pumps, tubing, cannulae, and membrane oxygenators is continuously exposed to artificial surfaces, potentially activating coagulation, inflammatory responses, and platelet activity. In addition, manufacturers must therefore balance high oxygen and carbon dioxide transfer efficiency with low resistance, minimal priming volume, reduced hemolysis, thrombosis prevention, and prolonged membrane durability. Oxygenator performance may also deteriorate over time due to clot formation, plasma leakage, or membrane fouling, potentially requiring circuit replacement.

Segmentation Analysis

By Product Type

Established Utilization Across ECMO and Cardiopulmonary Support to Drive the Artificial Lung Oxygenators Segment

Based on product type, the market is segmented into ECMO artificial lung systems, ECCO₂R systems, artificial lung oxygenators, portable artificial lung systems, and others.

The artificial lung oxygenators segment held the highest share of the global market in 2025. Artificial lung oxygenators perform the core gas-exchange function within extracorporeal circuits by facilitating oxygen transfer into blood and carbon dioxide removal. Moreover, their extensive utilization across cardiopulmonary bypass and extracorporeal respiratory-support procedures, recurring replacement requirements, and availability of adult and pediatric configurations support segment dominance.     

The portable artificial lung systems segment is anticipated to rise at the highest CAGR of 11.8% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

High Requirement for Advanced Oxygenation Support to Drive the Acute Hypoxemic Respiratory Failure Segment

Based on application, the market is segmented into acute hypoxemic respiratory failure, cardiopulmonary failure, chronic & end-stage lung failure, and others.

The acute hypoxemic respiratory failure segment accounted for the highest global artificial lung market share in 2025. Patients experiencing severe impairment of pulmonary oxygen exchange may require extracorporeal support when mechanical ventilation and conventional critical-care interventions cannot maintain adequate oxygenation. In addition, ECMO enables blood oxygenation outside the body while potentially allowing reduction of injurious ventilatory pressures in selected critically ill patients. The large clinical burden of severe pneumonia, acute respiratory distress syndrome, and other causes of refractory respiratory failure supports segment dominance.

The chronic & end-stage lung failure segment is projected to register the highest CAGR of 9.4% during the forecast period.

By Patient Type

Higher Incidence of Severe Respiratory and Cardiopulmonary Conditions to Drive the Adult Segment

Based on patient type, the market is segmented into adult and pediatric.

The adult segment accounted for the highest market share in 2025. Adults represent the majority of patients receiving extracorporeal respiratory and cardiopulmonary support due to the higher overall incidence of severe respiratory failure, cardiovascular disease, complex cardiac procedures, advanced pulmonary disease, and other critical illnesses requiring extracorporeal life support. Availability of a broad range of adult ECMO circuits, oxygenators, pumps, and cannulae further supports segment dominance.

The pediatric segment is projected to register considerable CAGR of 6.0% during the forecast period.

By End User

Requirement for Specialized Critical-Care Infrastructure to Drive the Hospitals Segment

Based on end user, the market is segmented into hospitals, academic & research institutes, and others.

The hospitals segment held the highest share of the global market in 2025. ECMO and other artificial lung technologies are predominantly utilized in hospitals with intensive-care units, cardiac surgery departments, transplant programs, perfusion services, and multidisciplinary teams capable of managing critically ill patients receiving extracorporeal support. In addition, availability of continuous monitoring, emergency intervention, blood-management capabilities, and specialized clinical personnel further supports segment dominance.

The academic & research institutes segment is projected to grow at a CAGR of 8.7% during the forecast period.

Artificial Lung Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valuing at USD 0.48 billion, and also maintained the leading share in 2025, with USD 0.50 billion. North America is expected to represent a major market owing to its established ECMO infrastructure, high concentration of tertiary and academic hospitals, advanced critical-care capabilities, significant cardiothoracic procedure volumes, and presence of major extracorporeal-support technology manufacturers.

U.S Artificial Lung Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be approximated at around USD 0.48 billion in 2026, accounting for roughly 35.5% of global artificial lung sales.

Europe

Europe is projected to record a considerable growth rate of 5.6% in the coming years, and reach a valuation of USD 0.38 billion by 2026. European market growth is attributed to established cardiac surgery and intensive-care infrastructure, extensive availability of extracorporeal life-support technologies, aging populations, and the presence of major cardiopulmonary device manufacturers.

U.K Artificial Lung Market

The U.K. market in 2026 is estimated at around USD 0.07 billion, representing roughly 5.0% of global artificial lung revenues.

Germany Artificial Lung Market

Germany’s market is projected to reach approximately USD 0.08 billion in 2026, equivalent to around 6.2% of global artificial lung sales.

Asia Pacific

Asia Pacific is estimated to hold considerable share in the global market and is estimated to reach USD 0.33 billion in 2026. Regional market growth is supported by expansion of tertiary hospitals and intensive-care infrastructure, increasing availability of ECMO programs, rising healthcare expenditure, growing cardiopulmonary disease burden, and improving access to advanced life-support technologies.

Japan Artificial Lung Market

The Japan market in 2026 is estimated at around USD 0.09 billion, accounting for roughly 6.5% of global artificial lung revenues.

China Artificial Lung Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 0.11 billion, representing roughly 8.3% of global artificial lung sales.

India Artificial Lung Market

The India market in 2026 is estimated at around USD 0.04 billion, accounting for roughly 2.6% of global artificial lung revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth during the forecast period. The Latin America market is set to reach a valuation of USD 0.06 billion in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 0.03 billion in 2026.

South Africa Artificial Lung Market

The South Africa market is projected to reach around USD 0.01 billion in 2026, representing roughly 0.8% of global artificial lung revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Advanced Oxygenator Technologies and Compact Extracorporeal Support Platforms to Shape Competition

The global artificial lung market has a semi-consolidated competitive structure, comprising prominent players such as Getinge AB, Medtronic plc, Fresenius Medical Care AG, Terumo Corporation, and LivaNova PLC. These companies compete through established extracorporeal life-support portfolios, oxygenator technologies, cannulation systems, global distribution networks, and relationships with cardiac surgery and intensive-care centers.

• For instance, in August 2026, LivaNova PLC entered into a long-term agreement with Thermo Fisher Scientific to strengthen the supply of a critical oxygenator component.

Other notable players in the global market Eurosets S.r.l., Nipro Corporation, Senko Medical Instrument Mfg. Co., Ltd., MicroPort Scientific Corporation, and Chinabridge (Shenzhen) Medical Technology Co., Ltd. These companies are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY ARTIFICIAL LUNG COMPANIES PROFILED

• Getinge AB (Sweden)
• Medtronic plc (Ireland)
• Fresenius Medical Care AG (Germany)
• Terumo Corporation (Japan)
• LivaNova PLC (UK)
• Eurosets S.r.l. (Italy)
• Nipro Corporation (Japan)
• Senko Medical Instrument Mfg. Co., Ltd. (Japan)
• MicroPort Scientific Corporation (China)
• Chinabridge (Shenzhen) Medical Technology Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENTS

• March 2026: Getinge received CE marking for Cardiohelp II, the next-generation version of its extracorporeal life-support platform.
• February 2026: Inspira Technologies deployed its FDA-cleared INSPIRA ART100 system at an additional major academic medical center in New York, initiating a structured commercial evaluation intended to define clinical protocols and evaluate broader institutional adoption of the extracorporeal blood-circulation platform.
• October 2025: Medtronic launched its VitalFlow ECMO system in Europe, expanding its extracorporeal life-support portfolio.
• April 2025: Eurosets introduced Landing Breathe and Xtreme Rescue at EuroELSO 2025.
• January 2025: CBM Lifemotion received European MDR CE Mark certification for its Lifemotion ECMO system, including its centrifugal pump, ECLS membrane oxygenator, integrated tubing set, and transport platform.

REPORT COVERAGE

The global artificial lung market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Country-Level Artificial Lung Utilization & Device Spending Analysis

• Estimate country-level demand using ECMO procedure volumes, cardiopulmonary bypass procedures, severe respiratory-failure patient populations, ECMO center availability, hospital capacity, product utilization, and manufacturer ASPs.
• Adjust for product mix, reusable versus disposable components, oxygenator replacement, procurement discounts, reimbursement, import dependence, and country-level pricing.
• Aggregate country estimates into regional and global totals.

Approach 2: Procedure Volume, Device Consumption & ASP Analysis

• Estimate annual artificial lung utilization across Acute Hypoxemic Respiratory Failure, Cardiopulmonary Failure, Chronic & End-Stage Lung Failure, and Others.
• Estimate devices and consumables used across ECMO Artificial Lung Systems, ECCO₂R Systems, Artificial Lung Oxygenators, Portable Artificial Lung Systems, and Others.
• Calculate market value using: Procedure Volume × Device Penetration × Product Utilization × Manufacturer ASP.
• Cross-check against manufacturer sales, ECMO procedure statistics, hospital utilization, product catalogs, and procurement data.

Approach 3: Secondary & Institutional Data Cross-Check

• Validate market assumptions using FDA, European regulatory authorities, ELSO, WHO, OECD, national healthcare authorities, transplant and critical-care databases, ClinicalTrials.gov, and peer-reviewed literature.
• Track regulatory approvals, product launches, ECMO utilization, oxygenator adoption, critical-care capacity, clinical trials, and geographic expansion.
• Exclude third-party market research estimates as primary evidence.

2. Top Down Approaches

Approach 1: Revenue & Market Share Analysis of Major Manufacturers/Developers

• Estimate artificial-lung-attributable revenues of major manufacturers using annual reports, regulatory filings, company disclosures, extracorporeal product portfolios, unit sales, installed base, oxygenator sales, ASPs, and geographic presence.
• Exclude unrelated cardiovascular, ventilator, anesthesia, hospital-service, and general medical-device revenues.
• Compare aggregated manufacturer revenues with bottom-up market estimates.

Approach 2: Triangulation, Validation and Forecast Modeling

• Compare manufacturer revenues, procedure-based demand, ECMO utilization, patient populations, device consumption, ASPs, regulatory approvals, and institutional data.
• Reconcile overestimation and underestimation using conservative, base-case, and higher-growth scenarios.
• Forecast country markets first, aggregate into regions, and then derive the global market.
• Calculate 2026–2034 CAGR using (2034 Market Size / 2026 Market Size) ^ (1/8) – 1.
• Ensure reconciliation across Product Type, Application, Patient Type, End User, country, region, and global totals.

3. List of Key Sources

• Company annual reports
• SEC and other regulatory filings
• Investor presentations
• Earnings disclosures
• Official company websites
• Product catalogs
• Instructions for use
• Product pricing documents
• S. FDA databases
• FDA 510(k) databases
• European Commission / EU MDR
• CE-marking documentation
• EUDAMED
• PMDA / MHLW
• NMPA
• CDSCO
• TGA
• WHO
• OECD
• World Bank
• Eurostat
• National ministries of health
• National healthcare databases
• Government procurement databases
• Hospital procurement and tender databases
• Extracorporeal Life Support Organization (ELSO)
• National critical-care societies
• Cardiothoracic surgery associations
• Lung-transplant organizations and registries
• gov
• PubMed
• Peer-reviewed critical-care journals
• Peer-reviewed cardiothoracic surgery journals
• Product-clearance announcements
• Product-registration databases
• Company press releases
• Acquisition announcements
• Partnership announcements
• Official distributor catalogs and listings

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents: ECMO system manufacturers, artificial lung oxygenator manufacturers, ECCO₂R manufacturers, portable artificial lung developers, extracorporeal pump manufacturers, membrane manufacturers, cannula manufacturers, tubing and circuit manufacturers, OEM/private-label suppliers, product managers, R&D executives, regulatory professionals, regional sales executives, commercial heads, and business-development executives.
• Validate artificial-lung-attributable manufacturer revenues.
• Validate system and oxygenator shipments.
• Validate installed base.
• Validate manufacturer ASPs.
• Validate recurring disposable and oxygenator revenues.
• Validate geographic sales mix.
• Validate Product Type mix.
• Validate Application mix.
• Validate Adult and Pediatric product exposure.
• Validate End User mix.
• Validate distribution structure.
• Validate regulatory registrations and geographic availability.
• Validate ECMO versus ECCO₂R product allocation.
• Validate oxygenator replacement frequency.
• Validate membrane technology adoption.
• Validate portable system development and commercialization.
• Validate product replacement cycles.
• Validate pricing trends.
• Validate geographic expansion.
• Validate expected technology migration through 2034.

Demand Side Interviews: 40%

• Key Respondents: Intensivists, pulmonologists, cardiothoracic surgeons, ECMO specialists, perfusionists, critical-care physicians, transplant physicians, hospital procurement executives, ICU administrators, ECMO program directors, clinical engineers, procurement professionals, and healthcare purchasing organizations.
• Validate annual ECMO and extracorporeal respiratory-support procedure volumes.
• Validate device and oxygenator utilization per procedure.
• Validate product preferences by clinical application.
• Validate oxygenator replacement requirements.
• Validate ASP ranges and procurement discounts.
• Validate utilization across Acute Hypoxemic Respiratory Failure, Cardiopulmonary Failure, Chronic & End-Stage Lung Failure, and Others.
• Validate utilization across Adult and Pediatric populations.
• Validate demand across Hospitals, Academic & Research Institutes, and Others.
• Validate ECMO versus ECCO₂R utilization.
• Validate portable versus conventional extracorporeal system preferences.
• Validate membrane oxygenator preferences.
• Validate cannulation and circuit requirements.
• Validate treatment duration and component replacement.
• Assess barriers including treatment cost, bleeding and thrombosis risk, infection, device malfunction, specialized staffing requirements, reimbursement limitations, and infrastructure availability.
• Validate future demand arising from expansion of ECMO centers, critical-care capacity, portable artificial lung development, chronic respiratory-support applications, transplant bridging, and increasing adoption of advanced extracorporeal technologies.